Stock AKBA AKEBIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
1.37 USD +0.74% Intraday chart for Akebia Therapeutics, Inc. -1.44% +10.48%
Apr. 23 Averoa Seeks EU Approval for Chronic Kidney Disease Drug MT
Apr. 16 Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement CI

Business Summary

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Number of employees: 167

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapeutics
100.0 %
292 100.0 % 195 100.0 % -33.46%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
292 100.0 % 195 100.0 % -33.46%

Managers

Managers TitleAgeSince
John Butler CEO
 Chief Executive Officer 59 13-06-30
Tracey Vetterick ADM
 Chief Administrative Officer - 22-03-31
Michel Dahan COO
 Chief Operating Officer 45 12-12-31
Steven Burke CTO
 Chief Tech/Sci/R&D Officer 63 19-06-16
Michael Rabinowitz CTO
 Chief Tech/Sci/R&D Officer - -
Mercedes Carrasco PRN
 Corporate Officer/Principal - -
Carolyn Rucci LAW
 General Counsel - 20-12-31
Meredith Bowman HRO
 Human Resources Officer - 22-04-30
Christian Barnes PRN
 Corporate Officer/Principal - -
Nicholas Grund PRN
 Corporate Officer/Principal 54 Jan. 08

Members of the board

Members of the board TitleAgeSince
Michael Rogers BRD
 Director/Board Member 64 18-12-11
Adrian Adams CHM
 Chairman 73 18-12-11
LeAnne M. Zumwalt BRD
 Director/Board Member 65 21-02-15
John Butler CEO
 Chief Executive Officer 59 13-06-30
Steven Gilman BRD
 Director/Board Member 71 18-12-11
Ronald Frieson BRD
 Director/Board Member 65 21-10-31
Cynthia Smith BRD
 Director/Board Member 55 18-08-27
Myles Wolf BRD
 Director/Board Member 53 20-04-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 209,372,275 187,998,029 ( 89.79 %) 0 89.79 %

Shareholders

NameEquities%Valuation
Alerce Investment Management LP
5.518 %
11,552,558 5.518 % 21 M $
Vanguard Global Advisers LLC
3.633 %
7,607,472 3.633 % 14 M $
Acadian Asset Management LLC
3.303 %
6,915,503 3.303 % 13 M $
Renaissance Technologies LLC
2.283 %
4,779,383 2.283 % 9 M $
Muneer Satter
2.222 %
4,652,561 2.222 % 9 M $
Millennium Management LLC
1.242 %
2,599,987 1.242 % 5 M $
BlackRock Institutional Trust Co. NA
1.201 %
2,514,860 1.201 % 5 M $
John Butler
1.129 %
2,364,436 1.129 % 4 M $
Susquehanna Securities LLC
1.031 %
2,159,364 1.031 % 4 M $
Jacobs Levy Equity Management, Inc.
0.8869 %
1,856,925 0.8869 % 3 M $

Company contact information

Akebia Therapeutics, Inc.

245 First Street Suite 1400

02142, Cambridge

+617 871 2098

http://www.akebia.com
address Akebia Therapeutics, Inc.(AKBA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Akebia Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.37 USD
Average target price
5 USD
Spread / Average Target
+264.96%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AKEBIA THERAPEUTICS, INC. Stock Akebia Therapeutics, Inc.
+10.48% 287M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
ARGENX SE Stock argenx SE
+1.86% 22.2B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
GENMAB A/S Stock Genmab A/S
-8.49% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AKBA Stock
  4. Company Akebia Therapeutics, Inc.